Akoya Biosciences (AKYA) Stock Forecast, Price Target & Predictions
AKYA Stock Forecast
Akoya Biosciences stock forecast is as follows: an average price target of $4.83 (represents a 89.41% upside from AKYA’s last price of $2.55) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
AKYA Price Target
The average price target for Akoya Biosciences (AKYA) is $4.83 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $7.50 to $3.00. This represents a potential 89.41% upside from AKYA's last price of $2.55.
AKYA Analyst Ratings
According to 5 Wall Street analysts, Akoya Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for AKYA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (60.00%), 2 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Akoya Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | Dave Westenberg | Piper Sandler | $4.00 | $2.32 | 72.41% | 56.86% |
| Aug 06, 2024 | Tejas Savant | Morgan Stanley | $3.00 | $2.01 | 49.25% | 17.65% |
| Jun 21, 2024 | Bill Bonello | Craig-Hallum | $7.50 | $2.23 | 236.32% | 194.12% |
| Jun 03, 2024 | Tejas Savant | Morgan Stanley | $4.00 | $2.15 | 86.05% | 56.86% |
| May 14, 2024 | Mark Massaro | BTIG | $6.00 | $4.12 | 45.63% | 135.29% |
| May 14, 2024 | Kyle Mikson | Canaccord Genuity | $6.00 | $4.12 | 45.63% | 135.29% |
| Aug 17, 2022 | David Westenberg | Piper Sandler | $17.00 | $13.34 | 27.44% | 566.67% |
The latest Akoya Biosciences stock forecast, released on Nov 15, 2024 by Dave Westenberg from Piper Sandler, set a price target of $4.00, which represents a 72.41% increase from the stock price at the time of the forecast ($2.32), and a 56.86% increase from AKYA last price ($2.55).
Akoya Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 6 |
| Avg Price Target | - | $4.00 | $5.08 |
| Last Closing Price | $2.55 | $2.55 | $2.55 |
| Upside/Downside | -100.00% | 56.86% | 99.22% |
In the current month, the average price target of Akoya Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Akoya Biosciences's last price of $2.55. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 15, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 06, 2024 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| Aug 06, 2024 | BTIG | Buy | Neutral | Downgrade |
| Jun 21, 2024 | Craig-Hallum | Buy | Initialise | |
| Jun 03, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
| May 15, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 14, 2024 | BTIG | Buy | Buy | Hold |
| May 14, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Jan 04, 2023 | BTIG | Buy | Buy | Hold |
| Aug 17, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Akoya Biosciences's last stock rating was published by Piper Sandler on Nov 15, 2024. The company gave AKYA a "Overweight" rating, the same as its previous rate.
Akoya Biosciences Financial Forecast
Akoya Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $26.49M | $25.21M | $23.52M | $21.41M | $21.22M | $18.85M | $17.89M | $16.89M | $16.16M | $13.48M | $13.07M | $12.21M |
| Avg Forecast | $29.91M | $27.38M | $26.45M | $22.16M | $25.78M | $23.04M | $22.64M | $20.05M | $21.47M | $25.29M | $23.43M | $24.35M | $26.14M | $24.51M | $22.39M | $20.32M | $20.47M | $17.59M | $16.92M | $14.93M | $15.52M | $13.06M | $12.59M | $12.03M |
| High Forecast | $31.85M | $29.15M | $28.17M | $23.59M | $27.45M | $24.53M | $24.11M | $21.76M | $22.15M | $25.51M | $23.49M | $24.35M | $26.25M | $24.51M | $23.84M | $21.63M | $21.79M | $17.59M | $16.92M | $14.93M | $15.52M | $13.06M | $12.59M | $12.03M |
| Low Forecast | $27.49M | $25.17M | $24.32M | $20.36M | $23.69M | $21.18M | $20.81M | $18.24M | $20.31M | $25.08M | $23.37M | $24.35M | $26.02M | $24.51M | $20.58M | $18.67M | $18.81M | $17.59M | $16.92M | $14.93M | $15.52M | $13.06M | $12.59M | $12.03M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.03% | 1.05% | 1.05% | 1.04% | 1.07% | 1.06% | 1.13% | 1.04% | 1.03% | 1.04% | 1.02% |
Akoya Biosciences's average Quarter revenue forecast for Mar 24 based on 4 analysts is $24.35M, with a low forecast of $24.35M, and a high forecast of $24.35M. AKYA's average Quarter revenue forecast represents a -8.09% decrease compared to the company's last Quarter revenue of $26.49M (Dec 23).
Akoya Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-11.20M | $-12.79M | $-16.23M | $-14.52M | $-14.80M | $-14.57M | $-16.08M | $-13.81M | $-21.87M | $-9.62M | $-3.68M | $-6.30M |
| Avg Forecast | $-14.15M | $-12.95M | $-12.51M | $-10.48M | $-12.19M | $-10.90M | $-10.71M | $-9.48M | $-10.16M | $-11.96M | $-11.08M | $-11.51M | $-12.36M | $-11.59M | $-10.59M | $-9.61M | $-9.68M | $-8.15M | $-7.84M | $-12.21M | $-7.19M | $-6.05M | $-5.83M | $-106.66M |
| High Forecast | $-13.00M | $-11.90M | $-11.50M | $-9.63M | $-11.21M | $-10.02M | $-9.84M | $-8.62M | $-9.61M | $-11.86M | $-11.05M | $-11.51M | $-12.30M | $-11.59M | $-9.73M | $-8.83M | $-8.90M | $-8.15M | $-7.84M | $-9.77M | $-7.19M | $-6.05M | $-5.83M | $-85.33M |
| Low Forecast | $-15.06M | $-13.79M | $-13.32M | $-11.16M | $-12.98M | $-11.60M | $-11.40M | $-10.29M | $-10.48M | $-12.06M | $-11.11M | $-11.51M | $-12.41M | $-11.59M | $-11.28M | $-10.23M | $-10.31M | $-8.15M | $-7.84M | $-14.66M | $-7.19M | $-6.05M | $-5.83M | $-127.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 1.10% | 1.53% | 1.51% | 1.53% | 1.79% | 2.05% | 1.13% | 3.04% | 1.59% | 0.63% | 0.06% |
undefined analysts predict AKYA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Akoya Biosciences's previous annual EBITDA (undefined) of $NaN.
Akoya Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-10.80M | $-12.92M | $-20.80M | $-18.80M | $-18.88M | $-17.87M | $-17.50M | $-16.40M | $-17.67M | $-11.62M | $-5.56M | $-8.08M |
| Avg Forecast | $-2.48M | $-3.22M | $-5.45M | $-9.16M | $-5.66M | $-7.14M | $-8.20M | $-9.97M | $-7.98M | $-9.90M | $-13.19M | $-14.29M | $-13.31M | $-17.68M | $-21.80M | $-23.70M | $-21.46M | $-21.72M | $-18.38M | $-14.30M | $-15.28M | $-12.85M | $-11.43M | $-136.92M |
| High Forecast | $-2.21M | $-2.88M | $-4.87M | $-8.20M | $-5.06M | $-6.39M | $-7.34M | $-8.55M | $-6.39M | $-8.86M | $-11.80M | $-12.79M | $-12.32M | $-15.82M | $-19.50M | $-21.21M | $-19.20M | $-21.72M | $-18.38M | $-11.44M | $-15.28M | $-12.85M | $-11.43M | $-109.53M |
| Low Forecast | $-2.68M | $-3.49M | $-5.90M | $-9.93M | $-6.13M | $-7.74M | $-8.89M | $-10.45M | $-9.58M | $-10.73M | $-14.30M | $-15.50M | $-14.29M | $-19.17M | $-23.63M | $-25.69M | $-23.27M | $-21.72M | $-18.38M | $-17.16M | $-15.28M | $-12.85M | $-11.43M | $-164.30M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.81% | 0.73% | 0.95% | 0.79% | 0.88% | 0.82% | 0.95% | 1.15% | 1.16% | 0.90% | 0.49% | 0.06% |
Akoya Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AKYA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Akoya Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $18.90M | $19.02M | $22.71M | $21.76M | $20.95M | $19.92M | $20.59M | $18.19M | $19.05M | $13.72M | $10.07M | $8.18M |
| Avg Forecast | $24.13M | $22.09M | $21.35M | $17.88M | $20.80M | $18.59M | $18.27M | $16.18M | $17.33M | $20.41M | $18.90M | $19.64M | $21.09M | $19.78M | $18.07M | $16.39M | $16.51M | $14.19M | $13.65M | $12.04M | $12.52M | $10.54M | $10.16M | $9.71M |
| High Forecast | $25.70M | $23.52M | $22.73M | $19.03M | $22.15M | $19.80M | $19.45M | $17.56M | $17.87M | $20.58M | $18.95M | $19.64M | $21.18M | $19.78M | $19.24M | $17.45M | $17.58M | $14.19M | $13.65M | $12.04M | $12.52M | $10.54M | $10.16M | $9.71M |
| Low Forecast | $22.18M | $20.31M | $19.62M | $16.43M | $19.12M | $17.09M | $16.79M | $14.71M | $16.39M | $20.24M | $18.86M | $19.64M | $20.99M | $19.78M | $16.61M | $15.07M | $15.18M | $14.19M | $13.65M | $12.04M | $12.52M | $10.54M | $10.16M | $9.71M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.90% | 0.96% | 1.26% | 1.33% | 1.27% | 1.40% | 1.51% | 1.51% | 1.52% | 1.30% | 0.99% | 0.84% |
Akoya Biosciences's average Quarter SG&A projection for Mar 24 is $19.64M, based on 4 Wall Street analysts, with a range of $19.64M to $19.64M. The forecast indicates a 3.95% rise compared to AKYA last annual SG&A of $18.90M (Dec 23).
Akoya Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.26 | $-0.51 | $-0.49 | $-0.50 | $-0.47 | $-0.47 | $-0.44 | $-0.47 | $-0.31 | $-0.20 | $-0.23 |
| Avg Forecast | $-0.05 | $-0.07 | $-0.11 | $-0.18 | $-0.11 | $-0.14 | $-0.17 | $-0.20 | $-0.16 | $-0.20 | $-0.27 | $-0.29 | $-0.27 | $-0.36 | $-0.44 | $-0.48 | $-0.43 | $-0.44 | $-0.37 | $-0.39 | $-0.31 | $-0.26 | $-0.23 | $-0.17 |
| High Forecast | $-0.04 | $-0.06 | $-0.10 | $-0.17 | $-0.10 | $-0.13 | $-0.15 | $-0.17 | $-0.13 | $-0.18 | $-0.24 | $-0.26 | $-0.25 | $-0.32 | $-0.39 | $-0.43 | $-0.39 | $-0.44 | $-0.37 | $-0.39 | $-0.31 | $-0.26 | $-0.23 | $-0.17 |
| Low Forecast | $-0.05 | $-0.07 | $-0.12 | $-0.20 | $-0.12 | $-0.16 | $-0.18 | $-0.21 | $-0.19 | $-0.22 | $-0.29 | $-0.31 | $-0.29 | $-0.39 | $-0.48 | $-0.52 | $-0.47 | $-0.44 | $-0.37 | $-0.39 | $-0.31 | $-0.26 | $-0.23 | $-0.17 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.73% | 1.16% | 1.02% | 1.15% | 1.07% | 1.26% | 1.14% | 1.52% | 1.19% | 0.86% | 1.35% |
According to undefined Wall Street analysts, Akoya Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AKYA previous annual EPS of $NaN (undefined).
Akoya Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKYA | Akoya Biosciences | $2.54 | $4.83 | 90.16% | Buy |
| ANGO | AngioDynamics | $9.26 | $13.00 | 40.39% | Buy |
| HAE | Haemonetics | $82.07 | $107.00 | 30.38% | Buy |
| ATRC | AtriCure | $31.50 | $39.67 | 25.94% | Buy |
| ATR | AptarGroup | $163.09 | $200.00 | 22.63% | Buy |
| COO | Cooper Companies | $94.49 | $115.00 | 21.71% | Buy |
| ICUI | ICU Medical | $157.17 | $190.50 | 21.21% | Buy |
| LMAT | LeMaitre Vascular | $90.93 | $98.00 | 7.78% | Buy |